IP Library Granted Patent US 9,546,128
Granted Patent B2
US 9,546,128 · App. 14/389,023 · Granted Jan 17, 2017

Ionizable cationic lipids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,546,128
App. No.
14/389,023
Granted
Jan 17, 2017
Kind
B2
Abstract

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Claims (50)

1. A compound having the structure:

wherein

R 1 and R 2 are each independently selected from the group consisting of hydrogen, an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently optionally substituted polyunsaturated C 6 -C 20 alkenyl;

m and o are each independently selected from the group consisting of zero and any positive integer; and

n is any positive integer.

2. A pharmaceutical composition comprising the compound of claim 1 .

3. A compound of having the structure:

4. The compound of claim 3 having the structure:

5. The compound of claim 3 having the structure:

6. A pharmaceutical composition comprising the compound of claim 3 .

7. The pharmaceutical composition of claim 6 , wherein the composition is a lipid nanoparticle.

8. The pharmaceutical composition of claim 7 , wherein the lipid nanoparticle is substantially non-toxic when administered to a subject.

9. The pharmaceutical composition of claim 8 , further comprising one or more therapeutic agents.

10. A compound having the structure:

wherein

R 1 and R 2 are each independently selected from the group consisting of an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently optionally substituted polyunsaturated C 6 -C 20 alkenyl; and

m, n and o are each independently selected from the group consisting of zero and any positive integer.

11. A pharmaceutical composition comprising the compound of claim 10 .

12. A compound having the structure:

13. A pharmaceutical composition comprising the compound of claim 12 .

14. The pharmaceutical composition of claim 13 , wherein the composition is a lipid nanoparticle.

15. The pharmaceutical composition of claim 14 , further comprising one or more therapeutic agents.

16. A compound having the structure:

wherein

R 1 and R 2 are each independently selected from the group consisting of an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently unsubstituted polyunsaturated C 18 alkenyl; and

x is selected from the group consisting of a C 5 -C 20 alkyl and a variably unsaturated C 1 -C 20 alkenyl.

17. A pharmaceutical composition comprising the compound of claim 16 .

18. The pharmaceutical composition of claim 17 , wherein the composition is a lipid nanoparticle.

19. The pharmaceutical composition of claim 17 , further comprising one or more polynucleotides.

20. A compound having the structure:

wherein R 1 and R 2 are each independently selected from the group consisting of an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

wherein

L 1 and L 2 are each independently unsubstituted polyunsaturated C 18 alkenyl; and

x is a C 1 -C 10 alkenyl.

21. A method of treating disease in a subject, wherein the method comprises administering an effective amount of the pharmaceutical composition of claim 9 to the subject.

22. A method of transfecting one or more target cells with a polynucleotide, wherein the method comprises contacting the one or more target cells with the pharmaceutical composition of claim 9 such that the one or more target cells are transfected with the polynucleotide.

23. The compound of claim 3 having the structure:

24. A method of treating disease in a subject, wherein the method comprises administering an effective amount of the pharmaceutical composition of claim 15 to the subject.

25. A method of treating disease in a subject, wherein the method comprises administering an effective amount of the pharmaceutical composition of claim 19 to the subject.

26. A method of transfecting one or more target cells with a polynucleotide, wherein the method comprises contacting the one or more target cells with the pharmaceutical composition of claim 15 such that the one or more target cells are transfected with the polynucleotide.

27. A method of transfecting one or more target cells with a polynucleotide, wherein the method comprises contacting the one or more target cells with the pharmaceutical composition of claim 19 such that the one or more target cells are transfected with the polynucleotide.

28. The compound of claim 1 , wherein o is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

29. The compound of claim 1 , wherein m is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

30. The compound of claim 1 , wherein n is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

31. The compound of claim 10 , wherein m is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

32. The compound of claim 10 , wherein n is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

33. The compound of claim 10 , wherein o is zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

Assignments (3)
CHANGE OF NAME Recorded Jul 20, 2017
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 043267/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 042177/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2014
From: DEROSA, FRANK; GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033963/0353 →